Sodium sulfate

Identification

Name
Sodium sulfate
Accession Number
DB09472
Description

Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate anhydrous is an electrolyte replenisher and is used in isosmotic solutions so that administration does not disturb normal electrolyte balance and does not lead to absorption or excretion of water and ions.

Type
Small Molecule
Groups
Approved, Vet approved
Structure
Thumb
Weight
Average: 142.042
Monoisotopic: 141.931268528
Chemical Formula
Na2O4S
Synonyms
  • Anhydrous sodium sulfate
  • Sodium sulfate anhydrous
  • Sodium sulfate, anhydrous
  • Sodium sulphate anhydrous
  • Sodium sulphate, anhydrous
  • Sulfuric acid disodium salt, anhydrous

Pharmacology

Indication

indicated for bowel cleansing prior to colonoscopy or barium enema X-ray examination.

Associated Therapies
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Induces catharsis by the osmotic effects of the unabsorbed sulfate salts and polyethylene glycol (PEG) in the GI tract. Specifically, sulfate salts provide sulfate anions, which are poorly absorbed, and PEG, which is primarily unabsorbed, causes water to be retained in the GI tract resulting in watery diarrhea.

Mechanism of action

MoviPrep produces a watery stool leading to cleansing of the colon. The osmotic activity of polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid, when taken with 1 liter of additional clear fluid, usually results in no net absorption or excretion of ions or water.

TargetActionsOrganism
ACarbonic anhydrase 2
inhibitor
Humans
ACarbonic anhydrase 1
inhibitor
Humans
Absorption

Absorption of sodium sulfate after ingestion in rats was investigated. 35)S-Radioactivity excreted in urine during 24 hr indicated almost complete absorption from GI tract. Determination in serum 2 hr after admin revealed 3-fold increase in sulfate concentration rapid and almost complete absorption of inorganic sulfate occurs after oral admin in rats.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Rectal effluent if unabsorbed sulfates ; urine (predominant route for absorbed sulfates )

Half-life

Serum sulfate: 8.5 hours

Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Mouse LD50 (Oral): 5989mg/kg Mouse LDLo (Intravenous): 1220mg/kg Rabbit LD50 (Intravenous):1220mg/kg

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
AcarboseAcarbose may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Sodium sulfate.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
AclidiniumAclidinium may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
AcrivastineSodium sulfate may decrease the excretion rate of Acrivastine which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

Products

Product Ingredients
IngredientUNIICASInChI Key
Sodium sulfate decahydrate0YPR65R21J7727-73-3RSIJVJUOQBWMIM-UHFFFAOYSA-L
Active Moieties
NameKindUNIICASInChI Key
Sodium cationionicLYR4M0NH3717341-25-2FKNQFGJONOIPTF-UHFFFAOYSA-N
Sulfate ionionic7IS9N8KPMG14808-79-8QAOWNCQODCNURD-UHFFFAOYSA-L
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Bi-peglyteSodium sulfate (5.74 g) + Bisacodyl (5 mg) + Polyethylene glycol (59.55 g) + Potassium chloride (0.76 g) + Sodium bicarbonate (1.69 g) + Sodium chloride (1.46 g)Kit; Powder, for solution; Tablet, delayed releaseOralPendopharm Division Of Pharmascience Inc2010-06-06Not applicableCanada flag
Clenz-LyteSodium sulfate (22.74 g/4L) + Polyethylene glycol (236 g/4L) + Potassium chloride (2.97 g/4L) + Sodium bicarbonate (6.74 g/4L) + Sodium chloride (5.86 g/4L)Powder, for solutionNasogastric; OralPaddock Laboratories, Inc.2010-06-072010-06-07US flag
ColPrep KitSodium sulfate decahydrate (17.5 g/22.7g) + Magnesium sulfate (1.6 g/22.7g) + Potassium sulfate (3.13 g/22.7g)Powder, for solutionOralKVK-Tech, Inc.2016-12-272019-01-24US flag
ColyteSodium sulfate (81.2 mg) + Polyethylene glycol (857.69 mg) + Potassium chloride (10.65 mg) + Sodium bicarbonate (24.02 mg) + Sodium chloride (20.87 mg)Powder, for solutionNasogastric; OralPendopharm Division Of Pharmascience Inc1986-12-31Not applicableCanada flag
ColyteSodium sulfate decahydrate (22.72 g/4L) + Polyethylene glycol (240 g/4L) + Potassium chloride (2.98 g/4L) + Sodium bicarbonate (6.72 g/4L) + Sodium chloride (5.84 g/4L)Powder, for solutionNasogastricMEDA Pharmaceuticals2014-08-052021-09-30US flag
ColyteSodium sulfate decahydrate (21.5 g/3.785L) + Polyethylene glycol (227.1 g/3.785L) + Potassium chloride (2.82 g/3.785L) + Sodium bicarbonate (6.36 g/3.785L) + Sodium chloride (5.53 g/3.785L)Powder, for solutionNasogastric; OralAlaven Pharmaceutical2010-09-012016-05-31US flag
Colyte with flavor packsSodium sulfate decahydrate (22.72 g/4L) + Polyethylene glycol (240 g/4L) + Potassium chloride (2.98 g/4L) + Sodium bicarbonate (6.72 g/4L) + Sodium chloride (5.84 g/4L)Powder, for solutionNasogastric; OralAlaven Pharmaceutical1999-04-072016-08-31US flag
Eau Purgative RigaSodium sulfate (1.056 g) + Magnesium sulfate (2.4 g)LiquidOralGlendale Agencies1978-12-311996-11-29Canada flag
Electropeg SolutionSodium sulfate (22.7 g) + Polyethylene glycol (238.8 g) + Potassium chloride (3 g) + Sodium bicarbonate (6.7 g) + Sodium chloride (5.8 g)PowderOralTechnilab Pharma Inc.1998-04-201999-09-27Canada flag
GaviLyte - C TMSodium sulfate (22.72 g/278.26g) + Polyethylene glycol (240 g/278.26g) + Potassium chloride (2.98 g/278.26g) + Sodium bicarbonate (6.72 g/278.26g) + Sodium chloride (5.84 g/278.26g)Powder, for solutionOralLupin Pharmaceuticals2009-01-06Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Sodium polysulthionate and folic acidSodium sulfate decahydrate (8 mg/1) + Folic acid (1 mg/1) + Octasulfur (388 mg/1) + Sodium thiosulfate pentahydrate (1.8 mg/1)CapsuleOralSolubiomix2016-08-242017-10-16US flag
Sodium polysulthionate, 5-methyltetrahydrofolateSodium sulfate decahydrate (2 g/100g) + Levomefolic acid (.125 g/100g) + Octasulfur (97 g/100g) + Sodium thiosulfate pentahydrate (.45 g/100g)PowderOral; TopicalSolubiomix2015-07-212016-01-12US flag
Sodium Polysulthionate, 5-mthfSodium sulfate decahydrate (8 mg/1) + 5-methyltetrahydrofolic acid (.5 mg/1) + Octasulfur (388 mg/1) + Sodium thiosulfate pentahydrate (1.8 mg/1)CapsuleOralSolubiomix2016-01-092016-01-12US flag
XizflusSodium sulfate decahydrate (2 g/100g) + 5-methyltetrahydrofolic acid (.125 g/100g) + Octasulfur (97 g/100g) + Sodium thiosulfate pentahydrate (.45 g/100g)PowderOral; TopicalBasiem2015-07-142016-01-12US flag
XizflusSodium sulfate decahydrate (8 mg/1) + 5-methyltetrahydrofolic acid (.5 mg/1) + Octasulfur (388 mg/1) + Sodium thiosulfate pentahydrate (1.8 mg/1)CapsuleOralBasiem2016-01-092016-01-12US flag

Categories

ATC Codes
A06AD13 — Sodium sulfateA12CA02 — Sodium sulfate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as alkali metal sulfates. These are inorganic compounds in which the largest oxoanion is sulfate, and in which the heaviest atom not in an oxoanion is an alkali metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkali metal oxoanionic compounds
Sub Class
Alkali metal sulfates
Direct Parent
Alkali metal sulfates
Alternative Parents
Inorganic sodium salts / Inorganic oxides
Substituents
Alkali metal sulfate / Inorganic oxide / Inorganic salt / Inorganic sodium salt
Molecular Framework
Not Available
External Descriptors
inorganic sodium salt (CHEBI:32149)

Chemical Identifiers

UNII
36KCS0R750
CAS number
7757-82-6
InChI Key
PMZURENOXWZQFD-UHFFFAOYSA-L
InChI
InChI=1S/2Na.H2O4S/c;;1-5(2,3)4/h;;(H2,1,2,3,4)/q2*+1;/p-2
IUPAC Name
disodium sulfate
SMILES
[Na+].[Na+].[O-]S([O-])(=O)=O

References

General References
  1. Morris ME, Levy G: Serum concentration and renal excretion by normal adults of inorganic sulfate after acetaminophen, ascorbic acid, or sodium sulfate. Clin Pharmacol Ther. 1983 Apr;33(4):529-36. [PubMed:6831833]
  2. Cocchetto DM, Levy G: Absorption of orally administered sodium sulfate in humans. J Pharm Sci. 1981 Mar;70(3):331-3. [PubMed:7264905]
  3. Pubchem [Link]
  4. DRUGS.COM [Link]
  5. DAILYMED [Link]
  6. ChemIDplus [Link]
  7. inChem [Link]
KEGG Drug
D01732
KEGG Compound
C13199
PubChem Compound
24436
PubChem Substance
347827857
ChemSpider
22844
BindingDB
50101993
RxNav
1299926
ChEBI
32149
ChEMBL
CHEMBL233406
Wikipedia
Sodium_sulfate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedNot AvailableColonoscopy1
4CompletedBasic ScienceFunctional Constipation / Irritable Bowel Syndrome Characterized by Constipation1
4CompletedDiagnosticColon Adenomas / Colon Lesion / Colon Polyps1
4CompletedScreeningColorectal Cancers1
4CompletedTreatmentBowel Preparation for Colonoscopy1
4CompletedTreatmentBowel preparation therapy / Colonoscopy / Endoscopy1
4CompletedTreatmentColon Cleansing for Colonoscopy1
4CompletedTreatmentColonoscopy2
4CompletedTreatmentColorectal Cleansing Prior Operation1
4CompletedTreatmentGastrointestinal Diseases1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Kit; powder, for solution; tablet, delayed releaseOral
Powder, for solutionOral52.5 g
Powder, for solutionNasogastric
Powder, for solutionOral45 g/750mL
LiquidOral
Powder, for solutionOral0.75 g/73.69g
Powder, for solutionNasogastric; Oral
Powder, for solutionOral14.75 G
Powder, for solutionOral29.5 G
Powder, for solutionOral7.375 G
Solution, concentrateOral17.51 g/176mL
SolutionOral3.276 g
Powder, for solutionOral1.685 g
PowderOral5 g/100mL
KitOral
SolutionOral100 g
Powder, for solutionOral4.7 g
Powder, for solutionOral7.5 g
Powder, for solutionOral118 g
Tablet, effervescentOral
Powder, for solutionOral59 g
Powder, for solutionOral100 g
Powder, for solutionOral
Powder, for solutionOral14.58 G
Powder, for solutionOral58.32 G
Powder, for solutionOral14.57 g
Powder, for solutionOral58.3 g
SolutionOral
PowderOral
Solution, concentrateOral
TabletOral
Granule, effervescentOral2.86 g
CapsuleOral
PowderOral; Topical
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US7169381No2007-01-302024-09-01US flag
US7658914No2010-02-092024-09-01US flag
US6946149No2005-09-202023-03-07US flag
US9326969No2016-05-032033-09-10US flag
US9592252No2017-03-142032-08-11US flag
US9707297No2017-07-182033-09-10US flag
US8999313No2015-04-072033-09-10US flag
US10016504No2018-07-102033-09-10US flag
US10646512No2012-03-252032-03-25US flag
US10792306No2012-03-092032-03-09US flag
US10780112No2012-03-092032-03-09US flag
Additional Data Available
  • Filed On
    Filed On
    Available for Purchase

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-0.84ChemAxon
pKa (Strongest Acidic)-3ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area80.26 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity11.53 m3·mol-1ChemAxon
Polarizability5.81 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
Gene Name
CA2
Uniprot ID
P00918
Uniprot Name
Carbonic anhydrase 2
Molecular Weight
29245.895 Da
References
  1. UniProt [Link]
  2. ChEMBL [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name
CA1
Uniprot ID
P00915
Uniprot Name
Carbonic anhydrase 1
Molecular Weight
28870.0 Da
References
  1. UniProt [Link]
  2. ChEMBL [Link]
  3. KEGG [Link]

Drug created on November 30, 2015 12:10 / Updated on January 09, 2021 11:41